Literature DB >> 22607516

Definition of advanced age in HIV infection: looking for an age cut-off.

José R Blanco1, Inmaculada Jarrín, Manuel Vallejo, Juan Berenguer, Carmen Solera, Rafael Rubio, Federico Pulido, Victor Asensi, Julia del Amo, Santiago Moreno.   

Abstract

The age of 50 has been considered as a cut-off to discriminate older subjects within HIV-infected people according to the Centers for Disease Control and Prevention (CDC). However, the International AIDS Society (IAS) mentions 60 years of age and the Department of Health and Human Services (DHHS) makes no consideration. We aimed to establish an age cut-off that could differentiate response to highly active antiretroviral therapy (HAART) and, therefore, help to define advanced age in HIV-infected patients. CoRIS is an open, prospective, multicenter cohort of HIV adults naive to HAART at entry (January 2004 to October 2009). Survival, immunological response (IR) (CD4 increase of more than 100 cell/ml), and virological response (VR) (HIV RNA less than 50 copies/ml) were compared among 5-year age intervals at start of HAART using Cox proportional hazards models, stratified by hospital and adjusted for potential confounders. Among 5514 patients, 2726 began HAART. During follow-up, 2164 (79.4%) patients experienced an IR, 1686 (61.8%) a VR, and 54 (1.9%) died. Compared with patients aged <25 years at start of HAART, those aged 50-54, 55-59, 60-64, 65-59, and 70 or older were 32% (aHR: 0.68, 95% CI: 0.52-0.87), 29% (aHR: 0.71, 95% CI: 0.53-0.96), 34% (aHR: 0.66, 95% CI: 0.46-0.95), 39% (aHR: 0.61, 95% CI: 0.37-1.00), and 43% (aHR: 0.57, 95% CI: 0.31-1.04) less likely to experience an IR. The VR was similar across all age groups. Finally, patients aged 50-59 showed a 3-fold increase (aHR: 3.58; 95% CI: 1.07-11.99) in their risk of death compared to those aged <30 years. In HIV infection, patients aged ≥50 years have a poorer immunological response to HAART and a poorer survival. This age could be used to define medically advanced age in HIV-infected people.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22607516      PMCID: PMC3423793          DOI: 10.1089/AID.2011.0377

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  52 in total

1.  Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis. Collaborative Group on AIDS Incubation and HIV Survival including the CASCADE EU Concerted Action. Concerted Action on SeroConversion to AIDS and Death in Europe.

Authors: 
Journal:  Lancet       Date:  2000-04-01       Impact factor: 79.321

2.  A case-control study of virological and immunological effects of highly active antiretroviral therapy in HIV-infected patients with advanced age.

Authors:  R Manfredi; F Chiodo
Journal:  AIDS       Date:  2000-07-07       Impact factor: 4.177

3.  Response to highly active antiretroviral therapy in HIV-infected patients aged 60 years or older after 24 months follow-up.

Authors:  H Knobel; A Guelar; G Valldecillo; A Carmona; A González; J L López-Colomés; P Saballs; J L Gimeno; A Díez
Journal:  AIDS       Date:  2001-08-17       Impact factor: 4.177

4.  Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study.

Authors:  T E Yamashita; J P Phair; A Muñoz; J B Margolick; R Detels; S J O'Brien; J W Mellors; S M Wolinsky; L P Jacobson
Journal:  AIDS       Date:  2001-04-13       Impact factor: 4.177

5.  Older HIV-positive patients in the era of highly active antiretroviral therapy: changing of a scenario.

Authors:  Mario Tumbarello; Ricardo Rabagliati; Katleen De Gaetano Donati; Silvia Bertagnolio; Enrica Tamburrini; Evelina Tacconelli; Roberto Cauda
Journal:  AIDS       Date:  2003-01-03       Impact factor: 4.177

6.  Comorbid conditions, treatment, and health maintenance in older persons with human immunodeficiency virus infection in New York City.

Authors:  Sanjiv S Shah; Joseph P McGowan; Cheryl Smith; Steve Blum; Robert S Klein
Journal:  Clin Infect Dis       Date:  2002-10-21       Impact factor: 9.079

7.  Clinical experience with human immunodeficiency virus-infected older patients in the era of effective antiretroviral therapy.

Authors:  Richard M Grimes; Max E Otiniano; Maria C Rodriguez-Barradas; Dejian Lai
Journal:  Clin Infect Dis       Date:  2002-05-08       Impact factor: 9.079

8.  Immunologic and clinical responses to highly active antiretroviral therapy over 50 years of age. Results from the French Hospital Database on HIV.

Authors:  Sophie Grabar; Isabelle Kousignian; Alain Sobel; Philippe Le Bras; Jacques Gasnault; Patricia Enel; Corinne Jung; Aba Mahamat; Jean-Marie Lang; Dominique Costagliola
Journal:  AIDS       Date:  2004-10-21       Impact factor: 4.177

9.  Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.

Authors:  Matthias Egger; Margaret May; Geneviève Chêne; Andrew N Phillips; Bruno Ledergerber; François Dabis; Dominique Costagliola; Antonella D'Arminio Monforte; Frank de Wolf; Peter Reiss; Jens D Lundgren; Amy C Justice; Schlomo Staszewski; Catherine Leport; Robert S Hogg; Caroline A Sabin; M John Gill; Bernd Salzberger; Jonathan A C Sterne
Journal:  Lancet       Date:  2002-07-13       Impact factor: 79.321

10.  Older age does not influence CD4 cell recovery in HIV-1 infected patients receiving highly active antiretroviral therapy.

Authors:  Mario Tumbarello; Ricardo Rabagliati; Katleen de Gaetano Donati; Silvia Bertagnolio; Eva Montuori; Enrica Tamburrini; Evelina Tacconelli; Roberto Cauda
Journal:  BMC Infect Dis       Date:  2004-11-06       Impact factor: 3.090

View more
  18 in total

1.  Self-rated health and substance use among individuals in HIV care in Rio de Janeiro, Brazil: a cross-sectional study.

Authors:  Iona K Machado; Paula M Luz; Jordan E Lake; Rodolfo Castro; Luciane Velasque; Jesse L Clark; Valdilea G Veloso; Beatriz Grinsztejn; Raquel B De Boni
Journal:  Int J STD AIDS       Date:  2017-02-02       Impact factor: 1.359

2.  Neurocognitive SuperAging in Older Adults Living With HIV: Demographic, Neuromedical and Everyday Functioning Correlates.

Authors:  Rowan Saloner; Laura M Campbell; Vanessa Serrano; Jessica L Montoya; Elizabeth Pasipanodya; Emily W Paolillo; Donald Franklin; Ronald J Ellis; Scott L Letendre; Ann C Collier; David B Clifford; Benjamin B Gelman; Christina M Marra; J Allen McCutchan; Susan Morgello; Ned Sacktor; Dilip V Jeste; Igor Grant; Robert K Heaton; David J Moore
Journal:  J Int Neuropsychol Soc       Date:  2019-03-20       Impact factor: 2.892

3.  Clinical characteristics and antiretroviral treatment of older HIV-infected patients.

Authors:  Mercedes Gimeno-Gracia; María José Crusells-Canales; María José Rabanaque-Hernández
Journal:  Int J Clin Pharm       Date:  2014-09-25

Review 4.  Dopaminergic impact of cART and anti-depressants on HIV neuropathogenesis in older adults.

Authors:  Stephanie M Matt; Peter J Gaskill
Journal:  Brain Res       Date:  2019-08-21       Impact factor: 3.252

5.  Frequency and Correlates of Subjective Cognitive Impairment in HIV Disease.

Authors:  David P Sheppard; Steven Paul Woods; Paul J Massman; Paul E Gilbert
Journal:  AIDS Behav       Date:  2019-03

6.  Cognitive and Physiologic Reserve Independently Relate to Superior Neurocognitive Abilities in Adults Aging With HIV.

Authors:  Rowan Saloner; Judith D Lobo; Emily W Paolillo; Laura M Campbell; Scott L Letendre; Mariana Cherner; Igor Grant; Robert K Heaton; Ronald J Ellis; David J Moore
Journal:  J Acquir Immune Defic Syndr       Date:  2022-08-01       Impact factor: 3.771

7.  Subjective cognitive decline disrupts aspects of prospective memory in older adults with HIV disease.

Authors:  Jennifer L Thompson; David P Sheppard; Anastasia Matchanova; Erin E Morgan; Shayne Loft; Steven Paul Woods
Journal:  Neuropsychol Dev Cogn B Aging Neuropsychol Cogn       Date:  2022-04-12

8.  Impact of Age-related Comorbidities on Five-year Overall Mortality among Elderly HIV-Infected Patients in the Late HAART Era--Role of Chronic Renal Disease.

Authors:  M Hentzien; M Dramé; C Allavena; C Jacomet; M-A Valantin; A Cabié; L Cuzin; D Rey; P Pugliese; F Bani-Sadr
Journal:  J Nutr Health Aging       Date:  2016-04       Impact factor: 4.075

Review 9.  Deprescribing of non-antiretroviral therapy in HIV-infected patients.

Authors:  José-Ramón Blanco; Ramón Morillo; Vicente Abril; Ismael Escobar; Enrique Bernal; Carlos Folguera; Fátima Brañas; Mercedes Gimeno; Olatz Ibarra; José-Antonio Iribarren; Alicia Lázaro; Ana Mariño; María-Teresa Martín; Esteban Martinez; Luis Ortega; Julian Olalla; Aguas Robustillo; Matilde Sanchez-Conde; Miguel-Angel Rodriguez; Javier de la Torre; Javier Sanchez-Rubio; Montse Tuset
Journal:  Eur J Clin Pharmacol       Date:  2019-12-21       Impact factor: 2.953

Review 10.  Role of mitochondria in HIV infection and associated metabolic disorders: focus on nonalcoholic fatty liver disease and lipodystrophy syndrome.

Authors:  P Pérez-Matute; L Pérez-Martínez; J R Blanco; J A Oteo
Journal:  Oxid Med Cell Longev       Date:  2013-07-21       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.